Profit before payment of interest, taxes and amortization: boundlessbio.com (BOLD)
Boundless Bio, Inc. (BOLD) is at the beginning of the precision oncology development cycle, where success depends on progress in cancer treatment. Demand here is non-cyclical and driven by medicine, while risks are limited to clinical phases. EBITDA cash flow captures real income on a daily basis, and the indicator value reaches 0.00. DNA analysis patents and the high cost of bioinformatics serve as the business's defensive assets.
Boundless Bio - analytical breakdowns and key metrics (BOLD)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- business book valuation details:
- business debt structure and liquidity details:
Total Debt to Capital Coefficient Boundless Bio, Inc.|BOLD - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Boundless Bio Inc.|BOLD - Company Aggregate Debts|Debt to Book Capitalization Ratio Boundless Bio|BOLD - Company Long-Term Debts|Short-Term Debt Volume Boundless Bio|Immediate Liquidity boundlessbio.com
- earnings and market multiples details:
BOLD - Net Income|Expected Net Income Boundless Bio, Inc.|BOLD - P/E Multiple|Market Cap to Projected Earnings boundlessbio.com|BOLD - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Boundless Bio|BOLD - Operating profit EBITDA|Net earnings per share for the last 12 months Boundless Bio|BOLD - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months boundlessbio.com|BOLD - Earnings growth in current year|Net earnings per share growth forecast for next year Boundless Bio, Inc.
Summary company analytics:Boundless Bio Inc (BOLD)
This metric measures the net cash flow generated by the core business before deducting tax and interest obligations, allowing for an assessment of actual operational efficiency. In the context of Boundless Bio, Inc. (BOLD), the operating financial result is not subject to market cyclicality; therefore, any deviations on the chart reflect exclusively internal clinical development costs, confirming the macro-stability of the company's fundamental position.
Who Boundless Bio, Inc. competes with
TEM: Operating profit before amortization|QGEN - Profit before payment of interest, taxes and amortization|IONS: Profit before payment of interest, taxes and amortization|RGEN: Operating profit EBITDA|Profit before interest, taxes and amortization Avidity Biosciences Inc (RNA)|Profit before payment of interest, taxes and amortization CRISPR Therapeutics Corp|GeneDx Corp (WGS) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|Operating income before deduction of amortization beamtx.com|Sarepta - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TWST|10x Genomics Corp - Operating profit EBITDA|NTLA: Profit before payment of interest, taxes and amortization|STOK: Operating profit EBITDA|BLFS - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Wave Life Sciences Ltd.|Profit before interest, taxes and amortization Maze Therapeutics, Inc. MAZE|Operating profit before deduction of amortization SION (Sionna Pharma)|PRME (Prime Medicine Bio) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TSHA (Taysha Gene Therapies)|Operating income before deduction of amortization uniqure.com (QURE)|MGTX - Profit before payment of interest, taxes and amortization|RGNX (REGENXBIO Inc) - Operating profit before amortization|SLDB: Operating profit EBITDA|Operating profit before deduction of amortization Ocugen Pharma|Operating profit before deduction of amortization PACB|benitec.com (BNTC) - Operating income before deduction of amortization|Operating profit EBITDA DSGN|Profit before payment of interest, taxes and amortization RCKT (Rocket Pharma)|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|Lexeo Therapeutics Inc. (LXEO) - Profit before interest, taxes and amortization|KRRO - Profit before payment of interest, taxes and amortization|EDIT: Profit before payment of interest, taxes and amortization|SLN: Operating profit EBITDA|Operating profit before amortization PRQR|CDXS (Codexis Inc) - Operating profit EBITDA|Operating profit before amortization SGMO (Sangamo BioSciences)|Profit before payment of interest, taxes and amortization Nautilus Biotechnology (NAUT)|metagenomi.co - Operating profit before amortization|Operating profit EBITDA DTIL (Precision BioSciences, Inc.)|Operating profit EBITDA Generation Bio Co GBIO|Exicure Corp - Operating profit EBITDA|IMNN: Profit before payment of interest, taxes and amortization|phiopharma.com (PHIO) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Mustang Bio (MBIO)|Operating profit before deduction of amortization RNAZ|Operating profit EBITDA Bionano|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|bluebird bio, Inc - Operating profit before amortization|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|OMGA: Operating profit before amortization|OMIC - Profit before payment of interest, taxes and amortization|RGLS: Profit before payment of interest, taxes and amortization|SYRS: Operating profit EBITDA|Profit before interest, taxes and amortization Telesis Bio, Inc (TBIO)|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|unitybiotechnology.com (UBX) - Operating income before deduction of amortization
